Engineered antibody maker KaloBios takes on $20M for clinical trials
South San Francisco, Calif.-based KaloBios Pharmaceuticals, which develops non-human antibodies for use in human bodies, has taken $20 million in its fourth round of venture funding.
KaloBios is currently going through seven first- and second-phase clinical trials for two drugs and is working on a third, newer drug. The drugs are aimed at patients with cystic fibrosis and autoimmune disorders like asthma.
Mitsubishi UFJ Capital and Genzyme Ventures co-led the round. Also participating were previous investors MPM Capital, Alloy Ventures, GBS Ventures, Sofinnova Ventures, Singapore Bioinnovations, 5AM Ventures and Lotus Bioscience Ventures.
Next Story: Smart grid company GridPoint heaps on $120M and buys electric vehicle startup V2Green
Previous Story: Connectiva raises $17M for telecom infrastructure
About the Author, Chris Morrison
Chris Morrison writes about cleantech and environmental issues for VentureBeat, with occasional forays into gaming and semantic technology. He got his start writing about tech for Business 2.0 magazine, but quickly realized new media was the ticket when that institution closed its doors in 2007. Chris has also covered public equities and regulatory issues. He originally hails from southern Virginia, graduated from Evergreen State College in Washington, and now lives in San Francisco.